4-oxo-6-[(4S)-4-phenyl-1,3-oxazolidine-3-carbonyl]-1H-pyridine-2-carboxylic acid | 1022893-26-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 4-oxo-6-[(4S)-4-phenyl-1,3-oxazolidine-3-carbonyl]-1H-pyridine-2-carboxylic acid
• CAS: 1022893-26-0
• 化学式: C₁₆H₁₄N₂O₅
• 分子量: 314.298
• InChiKey: UDBRDRAVYZVTNY-CQSZACIVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  95.9
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  4-oxo-6-[(4S)-4-phenyl-1,3-oxazolidine-3-carbonyl]-1H-pyridine-2-carboxylic acid 、 (2S,3S)-3-amino-2-hydroxy-4-phenyl-N-[3-(2H-tetrazol-5-yl)phenyl]butanamide;hydrochloride 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 KMI-1030
  参考文献：
  名称：

  Novel non-peptidic and small-sized BACE1 inhibitors

  摘要：

  Recently, we reported substrate-based beta-secretase (BACE1) inhibitors with a hydroxymethylcarbonyl (HMC) isostere as a substrate transition-state mimic. These inhibitors showed potent BACE1 inhibitory activities (similar to 1.2 nM IC50). In order to improve in vivo enzymatic stability and permeability across the blood-brain barrier, these penta-peptidic inhibitors would need to be further optimized. On the other hand, non-peptidic inhibitors possessing isophthalic residue at the P-2 position were reported from other research groups. We selected isophthalic-type aromatic residues at the P-2 position and an HMC isostere at the P-1 position as lead compounds. On the basis of the design approach focused on the conformer of docked inhibitor in BACE1, we found novel non-peptidic and small-sized BACE1 inhibitors possessing a 2,6-pyridinedicarboxylic, chelidamic or chelidonic residue at the P2 position. (c) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.01.056
• 作为产物：
  描述：

  4-氧代-1,4-二氢-2,6-吡啶二甲酸 、 (S)-4-phenyloxazolidine 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 4-oxo-6-[(4S)-4-phenyl-1,3-oxazolidine-3-carbonyl]-1H-pyridine-2-carboxylic acid
  参考文献：
  名称：

  Novel non-peptidic and small-sized BACE1 inhibitors

  摘要：

  Recently, we reported substrate-based beta-secretase (BACE1) inhibitors with a hydroxymethylcarbonyl (HMC) isostere as a substrate transition-state mimic. These inhibitors showed potent BACE1 inhibitory activities (similar to 1.2 nM IC50). In order to improve in vivo enzymatic stability and permeability across the blood-brain barrier, these penta-peptidic inhibitors would need to be further optimized. On the other hand, non-peptidic inhibitors possessing isophthalic residue at the P-2 position were reported from other research groups. We selected isophthalic-type aromatic residues at the P-2 position and an HMC isostere at the P-1 position as lead compounds. On the basis of the design approach focused on the conformer of docked inhibitor in BACE1, we found novel non-peptidic and small-sized BACE1 inhibitors possessing a 2,6-pyridinedicarboxylic, chelidamic or chelidonic residue at the P2 position. (c) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.01.056

文献信息

• NOVEL COMPOUND HAVING SECRETASE INHIBITORY ACTIVITY
  申请人：Kiso, Yoshiaki

  公开号：EP2168947A1

  公开（公告）日：2010-03-31

  A novel compound represented by the formula (1) below which has β-secretase inhibitory activity, its pharmaceutically acceptable salt or a prodrug thereof. wherein Ar is a substituted or unsubstituted 5 to 6 membered mono cyclic aromatic group; R1, R2 and R3 are hydrogen atom, substituted or unsubstituted alkyl group or the like, or R2 and R3 may be taken together with the adjacent nitrogen atom and carbon atom respectively to form a 3 to 6 membered ring; R4 is C1-6 alkyl group, C1-6 alkyl group substituted by phenyl, phenylthio, or a hetero ring, or the like; A is represented by the formula below: wherein X and Y are oxygen atom, NH or sulfur atom, Z is hydrogen atom, hydroxy group which may be substituted, amino group, thiol group, or the like; and B is hydroxy group, substituted or unsubstituted amino group, substituted or unsubstituted aliphatic or aromatic amino group, or the like.

  下面的公式（1）表示的一种新化合物具有β-分泌酶抑制活性，其药用可接受的盐或其前药。其中Ar是取代或未取代的5至6个成员单环芳香基团；R1、R2和R3是氢原子，取代或未取代的烷基或类似物，或R2和R3可以分别与相邻的氮原子和碳原子结合形成3至6个成员环；R4是C1-6烷基，C1-6烷基被苯基，苯硫基或杂环取代，或类似物取代；A由以下公式表示：其中X和Y是氧原子，NH或硫原子，Z是氢原子，可被取代的羟基，氨基，硫醇基等；B是羟基，取代或未取代的氨基，取代或未取代的脂肪或芳香氨基，或类似物。
• NOVEL COMPOUND HAVING BETA-SECRETASE INHIBITORY ACTIVITY
  申请人：Kiso Yoshiaki

  公开号：US20100137606A1

  公开（公告）日：2010-06-03

  A novel compound represented by the formula (1) below which has β-secretase inhibitory activity, its pharmaceutically acceptable salt or a prodrug thereof. wherein Ar is a substituted or unsubstituted 5 to 6 membered mono cyclic aromatic group; R 1 , R 2 and R 3 are hydrogen atom, substituted or unsubstituted alkyl group or the like, or R 2 and R 3 may be taken together with the adjacent nitrogen atom and carbon atom respectively to form a 3 to 6 membered ring; R 4 is C 1-6 alkyl group, C 1-6 alkyl group substituted by phenyl, phenylthio, or a hetero ring, or the like; A is represented by the formula below: wherein X and Y are oxygen atom, NH or sulfur atom, Z is hydrogen atom, hydroxy group which may be substituted, amino group, thiol group, or the like; and B is hydroxy group, substituted or unsubstituted amino group, substituted or unsubstituted aliphatic or aromatic amino group, or the like.
• US8344002B2
  申请人：——

  公开号：US8344002B2

  公开（公告）日：2013-01-01
• Novel non-peptidic and small-sized BACE1 inhibitors
  作者：Yoshio Hamada、Hiroko Ohta、Naoko Miyamoto、Ryoji Yamaguchi、Abdellah Yamani、Koushi Hidaka、Tooru Kimura、Kazuki Saito、Yoshio Hayashi、Shoichi Ishiura、Yoshiaki Kiso

  DOI：10.1016/j.bmcl.2008.01.056

  日期：2008.3

  Recently, we reported substrate-based beta-secretase (BACE1) inhibitors with a hydroxymethylcarbonyl (HMC) isostere as a substrate transition-state mimic. These inhibitors showed potent BACE1 inhibitory activities (similar to 1.2 nM IC50). In order to improve in vivo enzymatic stability and permeability across the blood-brain barrier, these penta-peptidic inhibitors would need to be further optimized. On the other hand, non-peptidic inhibitors possessing isophthalic residue at the P-2 position were reported from other research groups. We selected isophthalic-type aromatic residues at the P-2 position and an HMC isostere at the P-1 position as lead compounds. On the basis of the design approach focused on the conformer of docked inhibitor in BACE1, we found novel non-peptidic and small-sized BACE1 inhibitors possessing a 2,6-pyridinedicarboxylic, chelidamic or chelidonic residue at the P2 position. (c) 2008 Elsevier Ltd. All rights reserved.